ArticleNanomedicine (London, England)2018
Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields.
Article in Nanomedicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Nanocarbon as a Quantum Material for Biointerfaces and Magnetic Platforms in Theranostic Biomedicine in Oncology: A Critical Review.Biosensors · 2026Review
- Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations.Drug delivery and translational research · 2026Review
- Foundational insights for theranostic applications of magnetoelectric nanoparticles.Nanoscale horizons · 2025Review
- Magnetoelectric Extracellular Vesicle Latency-Targeting (MELT) Nanotherapeutic for the Block-Lock-and-Kill HIV Eradication Strategy.Biomedicines · 2025Article
- Theoretical Modeling of the Interactions of CoFeCurrent medicinal chemistry · 2025Article
- Innovative nanoparticle-based therapeutic strategies against glioblastoma multiform: a focus on enhanced delivery systems and efficacy.Frontiers in bioengineering and biotechnology · 2025Review
- Catalytic Degradation of Organic Dyes Indicates Anti-Proliferative Effects of Magnetoelectric Nanoparticles.Journal of electronic materials · 2025Article
- Investigating the neuroprotective properties of3 Biotech · 2025Article
- Overcoming the Blood-Brain Barrier: Multifunctional Nanomaterial-Based Strategies for Targeted Drug Delivery in Neurological Disorders.Small science · 2024Article
- Advances in Brain Stimulation, Nanomedicine and the Use of Magnetoelectric Nanoparticles: Dopaminergic Alterations and Their Role in Neurodegeneration and Drug Addiction.Molecules (Basel, Switzerland) · 2024Review
- Article
- Low-frequency magnetic fields potentiate plasma-modified magneto-electric nanoparticle drug loading for anticancer activity in vitro and in vivo.Scientific reports · 2023Article
- Synthesis and Functional Characterization of CoNanomaterials (Basel, Switzerland) · 2023Article
- Review
- Biocompatible, Multi-Mode, Fluorescent,Pharmaceuticals (Basel, Switzerland) · 2022Article
- Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles.Biosensors · 2022Review
- Metal-Based Nanostructured Therapeutic Strategies for Glioblastoma Treatment-An Update.Biomedicines · 2022Review
- Recent advances, status, and opportunities of magneto-electric nanocarriers for biomedical applications.Molecular aspects of medicine · 2022Review
- Article
- Magnetic nanoparticles in theranostics of malignant melanoma.EJNMMI research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
aimWe studied externally controlled anticancer effects of binding tumor growth inhibiting synthetic peptides to magnetoelectric nanoparticles (MENs) on treatment of glioblastomas.
methodsHydrothermally synthesized 30-nm MENs had the core-shell composition of CoFe
resultsThe studies demonstrated externally controlled high-efficacy binding of MIA690 to MENs, targeted specificity to glioblastoma cells and on-demand release of the peptide by application of d.c. and a.c. magnetic fields, respectively.
conclusionThe results support the use of MENs as an effective drug delivery carrier for growth hormone-releasing hormone antagonists in the treatment of human glioblastomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.